126 related articles for article (PubMed ID: 30557403)
21. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
22. Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques.
Chopra A; Soni S; Pati H; Kumar D; Diwedi R; Verma D; Vishwakama G; Bakhshi S; Kumar S; Gogia A; Kumar R
Indian J Med Res; 2016 Jun; 143(6):763-768. PubMed ID: 27748301
[TBL] [Abstract][Full Text] [Related]
23. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
[TBL] [Abstract][Full Text] [Related]
24. Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules.
Liso A; Colau D; Benmaamar R; De Groot A; Martin W; Benedetti R; Specchia G; Martelli MP; Coulie P; Falini B
Leukemia; 2008 Feb; 22(2):424-6. PubMed ID: 17690700
[No Abstract] [Full Text] [Related]
25. Role of nucleophosmin in acute myeloid leukemia.
Meani N; Alcalay M
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1283-94. PubMed ID: 19761432
[TBL] [Abstract][Full Text] [Related]
26. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.
Suzuki R; Onizuka M; Kojima M; Shimada M; Okamura K; Fukagawa S; Tsuboi K; Kikuchi A; Kobayashi H; Shintani A; Ogawa Y; Kawada H; Hotta T; Ando K
Int J Hematol; 2007 Dec; 86(5):422-8. PubMed ID: 18192111
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
[TBL] [Abstract][Full Text] [Related]
29. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
[TBL] [Abstract][Full Text] [Related]
30. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
31. NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes.
Darracq A; Pak H; Bourgoin V; Zmiri F; Dellaire G; Affar EB; Milot E
PLoS Genet; 2019 Nov; 15(11):e1008463. PubMed ID: 31675375
[TBL] [Abstract][Full Text] [Related]
32. KIR2DS3 is associated with protection against acute myeloid leukemia.
Shahsavar F; Tajik N; Entezami KZ; Fallah Radjabzadeh M; Asadifar B; Alimoghaddam K; Ostadali Dahaghi M; Jalali A; Ghashghaie A; Ghavamzadeh A
Iran J Immunol; 2010 Mar; 7(1):8-17. PubMed ID: 20371915
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
Falini B; Sportoletti P; Martelli MP
Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
[TBL] [Abstract][Full Text] [Related]
35. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
36. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
37. HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia.
Guo QY; Chen BG; Ruan YY; Lin A; Yan WH
Leuk Res; 2011 Oct; 35(10):1350-4. PubMed ID: 21696824
[TBL] [Abstract][Full Text] [Related]
38. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
Falini B; Mecucci C; Tiacci E; Alcalay M; Rosati R; Pasqualucci L; La Starza R; Diverio D; Colombo E; Santucci A; Bigerna B; Pacini R; Pucciarini A; Liso A; Vignetti M; Fazi P; Meani N; Pettirossi V; Saglio G; Mandelli F; Lo-Coco F; Pelicci PG; Martelli MF;
N Engl J Med; 2005 Jan; 352(3):254-66. PubMed ID: 15659725
[TBL] [Abstract][Full Text] [Related]
39. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
40. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]